Lyme Disease Testing Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The Lyme disease testing market comprises a range of diagnostic products and services including enzyme immunoassays, immunofluorescence assays, Western blot tests, and emerging molecular diagnostic techniques. These tests are used to confirm or rule out Lyme disease infection in patients presenting with symptoms or tick exposure histories. The sector reflects broader trends in infectious disease diagnostics, with demand shaped by epidemiological patterns, healthcare access, and clinical practice guidelines.

• •Market valued at approximately $4.76 billion in 2025
• •Projected to grow at 5.9% compound annual growth rate
• •Encompasses ELISA, Western blot, and PCR-based testing modalities

Increasing prevalence of Lyme disease across endemic regions, particularly in North America and Europe, serves as a fundamental driver of market expansion. Enhanced awareness among clinicians and the general population leads to higher testing rates and earlier diagnosis. Furthermore, advancements in diagnostic technologies, including improved two-tiered testing algorithms and molecular methods, support market growth by delivering better clinical outcomes.

• •Rising incidence of Lyme disease in established and emerging endemic areas
• •Improved diagnostic technologies enhancing test sensitivity and specificity
• •Public health initiatives promoting tick-borne disease awareness and surveillance

The market segments by diagnostic technology, sample type, patient type, and end-use setting, with laboratory-based testing representing the largest segment. North America commands the dominant market share due to high disease prevalence, established healthcare infrastructure, and widespread insurance coverage for diagnostic testing. Europe constitutes a significant secondary market, while Asia-Pacific and other regions are witnessing gradual growth as diagnostic capabilities expand and disease recognition improves.

• •Segmentation includes test type (ELISA, Western blot, PCR), sample type (blood, CSF), and end user (hospitals, independent laboratories, clinics)
• •North America leads market share due to high Lyme disease incidence and advanced healthcare infrastructure
• •Europe and emerging markets show growing adoption of advanced diagnostic platforms

What are the recent trends and outlook?

The market is expected to maintain steady growth through the early 2030s, with various industry analyses projecting substantial expansion over the forecast horizon. Emerging trends include development of rapid point-of-care tests, multiplex assays that screen for multiple tick-borne pathogens simultaneously, and incorporation of digital technologies in test interpretation and reporting. The recognition of co-infections and the broadening geographic range of tick-borne diseases present opportunities for comprehensive testing panels and personalized diagnostic approaches.

• •Continued growth projected through 2032 and beyond as diagnostic access expands globally
• •Growing demand for rapid point-of-care and at-home Lyme disease testing options
• •Development of multiplex and next-generation sequencing assays for comprehensive tick-borne disease detection